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Background: Vascular complications curtail life expectancy and quality of life in type 1 diabetes and development
at younger ages is particularly detrimental. To date no review has summarised the prevalence or factors predicting
their development in young adults.
Methods: A quantitative epidemiological systematic review was conducted to identify the prevalence and
predictive factors for development of retinopathy, nephropathy and hypertension in young adults (sample age
mean [plus 1SD] 18–30 years) with type 1 diabetes, using processes adapted from established review methods set
out by the Centre for Reviews and Dissemination.
MEDLINE (Ovid), Scopus (Elsevier), CINAHL, Science Direct (Elsevier), Google Scholar and Cochrane databases were
searched to identify relevant articles published between 1993 and June 2014. From this eleven papers were
retrieved, appraised and results summarised by three reviewers using established methods.
Results: Some form of retinopathy occurred in up to almost half of participants; more severe forms affected up to
one in ten. One in six was reported with microalbuminuria; one in 14 had macroalbuminuria. Hypertension
occurred in almost one in two participants. Applying out-dated high thresholds this decreased to approximately
one in ten participants. Glycaemic control was a consistent predictor of vascular disease in this age group.
Conclusion: Prevalence rates of retinopathy, nephropathy and hypertension in young adults with type 1 diabetes
emphasise the importance of regular complication screening for early detection and treatment. The predictive
effect of glycaemic control reinforces its importance for prevention of vascular complications.
Keywords: Quantitative epidemiological systematic review, Vascular complications, Prevalence, Predictors,
Retinopathy, Nephropathy, Hypertension, Young adults, Type 1 diabetesBackground
The increasing incidence of type 1 diabetes in many
countries challenges health systems because the disease
is presently incurable with no known method of preven-
tion [1]. Around 490,100 children live with the disease
worldwide, with incidence estimated to be increasing in
children under 15 years by 2.8% per year [1,2]. This
trend is particularly worrying because type 1 diabetes
increases mortality and morbidity population-wide, includ-
ing in young adults [3-5]. People with type 1 diabetes* Correspondence: Steven.B.James-1@student.uts.edu.au
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unless otherwise stated.diagnosed before the age of 30 years have been calculated
to have a 4.7-fold excess mortality risk [6].
Vascular complications are often the cause of this early
mortality. However, there is currently little information
available about the prevalence or predictive factors for
development of vascular complications of type 1 dia-
betes among young adults. Identification of disease com-
plication prevalence and any predictive characteristics
will establish a benchmark of these risk factors, and may
assist healthcare professionals to target appropriate infor-
mation and support with the aim of deferring or averting
their onset.
The development of vascular disease in type 1 diabetes
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thelial function, inflammation, coagulation, platelet activa-
tion and fibrinolysis [7]. In combination with population-
wide cardiovascular and athero-thrombosis risk factors, a
state of persistent and progressive damage to the vascular
wall (macro-angiopathy) is created [8]. Micro-angiopathic
disease also occurs, with hyperglycaemia a leading patho-
genic factor [9]. Vascular co-morbid diseases include retin-
opathy, which may cause reduced vision and blindness, and
nephropathy, which may result in renal failure and require
dialysis or kidney transplantation. This is in addition to
hypertension, which is linked to peripheral, cardio- and
cerebrovascular disease, the end points of which are limb
amputations, cardiac failure, stroke and sudden death. As
vascular complications curtail both life expectancy and
quality of life [10], development at younger ages when
people are typically establishing careers and families is par-
ticularly detrimental.
Young adults may be particularly vulnerable to com-
plications because many have unique health needs relat-
ing to their psychological, physical and socio-cultural life
stage issues; these commonly lie outside health services’ re-
mit and place them at high risk for poor self-management.
Diabetes services are predominantly structured into exclu-
sive paediatric and adult services, with transition between
these services not clearly the responsibility of either: an
arrangement which serves young adults poorly. This transi-
tion stage was first formally identified as challenging by
Blum et al. [11], however, decades later similar levels of dif-
ficulty with the transition process are still being reported
[12]. Consequently, young adults with type 1 diabetes may
not adhere to diabetes regimes, and may disengage from
diabetes services after transition [13,14]. Attrition from, or
failure to engage with, diabetes services as an adult too-
frequently results in reduced diabetes self-management and
well-being, and inadequate screening for complications.
The potential benefits of models of transition to maintain
engagement with adult diabetes services post-transfer from
paediatric care have been flagged, and characteristics asso-
ciated with reduced attrition and increased satisfaction and
successful service redesign described [15-17]. However, the
effect of transition service redesign has not been examined
in terms of outcomes such as onset of vascular complica-
tions; neither has there been any attempt to summate or
quantify the degree of complication-related morbidity and
early mortality experienced by this young adult group. Lack
of international benchmarks limits evaluation and deters
appropriate prioritisation of service redesign to promote
retention of young adults in contact with services, an essen-
tial element in achieving good glycaemic control to defer
onset of complications [18-20].
The aim of this review was to identify the prevalence
and factors predictive of development of vascular com-
plications (retinopathy, nephropathy and hypertension)occurring in young adults with type 1 diabetes. For the
purpose of this review, the term young adult refers to
ages 18–30 years inclusive.
Methods
A quantitative epidemiological systematic review was
conducted using processes adapted from established
review methods set out by the Centre for Reviews and
Dissemination [21]. Standards derived from the Preferred
Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA) were applied [22]. The review protocol is
available from the authors on request.
Outcome definitions and recommended measurement
methods
Definitions and criteria for ‘best practice’ screening
methods for retinopathy, nephropathy and hypertension
were sought. Detailed recommendations were available in
American, Canadian and British guidelines [23-25]:
Diabetic retinopathy
The presence and characteristic evolution of typical ret-
inal microvascular lesions in an individual with diabetes.
Besides micro-aneurysms, blood vessel changes include
intra-retinal haemorrhage, and vascular tortuosity and
malformation (non-proliferative retinopathy) leading to
abnormal vessel development (proliferative retinopathy).
Seven-standard field stereoscopic-colour fundus photog-
raphy with interpretation by a trained reader is the rec-
ommended standard screening for diabetic retinopathy,
though direct ophthalmoscopy or indirect slit-lamp fundos-
copy through dilated pupil or digital fundus photography
may also be used. Treatment with laser photocoagulation
surgery prevents vision loss [26-29]. The Canadian Diabetes
Association Clinical Practice Guidelines Expert Committee
[24] advocates that screening should be undertaken at
least annually. However, the American Diabetes Asso-
ciation [23] advocates consideration of lesser frequency
(every two - three years) following one or more normal
eye examinations.
Nephropathy
A glomerular filtration rate (GFR) less than 60 mL/min
present for three or more months, or any evidence of
kidney damage for three or more months regardless of
GFR [30]. In addition to any anatomical or pathological
abnormalities or glomerular haematuria, it can be revealed
by micro- or macroalbuminuria/proteinuria. Screening for
nephropathy in adults with diabetes entails estimation of
the level of kidney function and assessment of urinary albu-
min excretion. Significantly reduced kidney function is evi-
denced by an estimated GFR less than 60 mL/min; serum
creatinine should be used to estimate GFR and stage the
level of chronic kidney disease. Albuminuria should be
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a random spot test to determine albumin to creatinine ratio
(ACR). The measurement of a spot urine for albumin, with-
out simultaneously measuring urine creatinine, is suscep-
tible to false negative/positive determinations.
Microalbuminuria was identified as urinary albumin
excretion of either 30–299 or 300 mg/day in a 24-hour
urine collection, with variations based on differing
guidelines [23,24], or an ACR of 2.0 - 20.0 mg/mmol.
Macroalbuminuria (overt nephropathy) was identified as
300 mg/day or above if a 24-hour urine collection was
performed, or an ACR of greater than 20.0 mg/mmol.
Blood pressure
Recommended targets are less than 130/80 mmHg for
people with diabetes. Measurement of blood pressure
should be undertaken by trained personnel, with partici-
pants in the seated position with feet on the floor and
arm supported at heart level, after five minutes of rest.
Cuff size must be appropriate for the arm circumference,
with elevated values confirmed on a separate day. The
American Diabetes Association [23] advocate that blood
pressure should be measured at every routine visit.
Literature search methods
MEDLINE (Ovid) and Scopus (which incorporates
Embase journals), CINAHL, Science Direct (Elsevier),
Google Scholar and Cochrane were searched by the
first author to June 2014 to identify relevant articles.
The MESH headings ‘Diabetes Mellitus, Type 1’; ‘Diabetic
Retinopathy’; ‘Diabetic Nephropathies’; ‘Hypertension’;
‘Prevalence’; ‘Cross-sectional Studies’; and ‘Prospective Stud-
ies’, and keywords ‘Type 1 diabetes’; ‘Insulin Dependent
Diabetes Mellitus’; ‘Juvenile Onset Diabetes Mellitus’; ‘Retin-
opathy’; ‘Eye Diseases’; ‘Nephropathy’; ‘Kidney Diseases’;
‘High Blood Pressure’; and Longitudinal Studies’ were used.
The full search strategy can be viewed in Additional file 1.
In addition, reference lists of all eligible studies were hand-
searched.
Inclusion criteria were:
 Samples with type 1 diabetes;
 Mean age (plus 1SD) 18–30 years, or where the
results for this age range were reported separately
from other age groups; and
 English language studies only due to lack of resources
for translation.
Exclusion criteria:
 Studies reporting data collected pre 1993 as from
this date the definitive Diabetes Control and
Complications Trial [9] established that the onset
and progression of micro-vascular complications canbe significantly reduced by HbA1c management.
This changed diabetes management to make
glycaemic control central, and hence management
and complication rates may have changed.
Search outcome
A total of 7,740 records were identified, downloaded to
EndNote version X4 and screened by reading titles and
abstracts. Of these, 7,601 records were excluded as du-
plicates or not meeting review inclusion criteria, includ-
ing 12 non-English language papers. The remaining 139
full-text articles were assessed for eligibility; their refer-
ence lists were searched and an additional 12 papers
identified. Of these 151 papers, 140 did not meet review
inclusion criteria, leaving eleven relevant papers [31-41].
The search process and outcomes are summarised in
Figure 1.
Quality appraisal
With no universally accepted ‘gold standard’ method for
evaluating and interpreting epidemiological study quality
[42], to determine the strength of evidence quality ap-
praisal was undertaken using the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) [43] checklist for cohort, case-control, and
cross-sectional studies. Eligible papers were also evalu-
ated for methods of assessment and measurement of
retinopathy, nephropathy and hypertension in relation
to current evidence-based guideline recommendations.
This appraisal can be viewed in Additional file 2. To en-
sure reliability in data extraction and quality appraisal, a
sample of papers included in the review were independ-
ently appraised and data extraction compared by the
second and last authors (six papers each). Agreement
was reached for all papers.
Data extraction and synthesis
Data were extracted to a purpose-designed spread-sheet
in Microsoft Office Excel based on relevant elements of
the Consolidated Standards of Reporting Trials (CON-
SORT) checklist [44]. Extracted data can be viewed in
Table 1 and Additional file 3. The number of diabetes
centres involved in each study was noted to aid inter-
pretation of transferability of findings.
Results
The eleven papers derived from nine separate studies
and mainly employed cross-sectional research designs;
three papers that had provided data applicable to the
target age group had involved a 1995 cohort of a Danish
nationwide longitudinal study [32,37,38]. Data were col-
lected via case note audit in three studies, and via docu-
mentation surveys in two further studies. Only three of
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language (n12), and content of titles/abstracts 
indicating they did not meet inclusion criteria 
Figure 1 Literature search and review flow chart.
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quality and are summarised in Table 1 and Additional
files 2 and 3. Ethnicity was reported in only three papers,
and only one study focused on rural/non-urban popula-
tions or localities.
Prevalence and prediction of retinopathy
The prevalence of diabetic retinopathy in the target popula-
tion was reported in seven papers [31,32,34,36-38,40].
Prevalence data were reported for 215 applicable partici-
pants by Arfken et al. [31], for both 95 (2010) and 85
(2011) participants by James et al. [34], and 53 by Salardi
et al. [40]. In longitudinal studies data were also reported
on 324 applicable participants by Broe et al. [32], on 290
at nine years diabetes duration by LeCaire et al. [36], on
190 by Olsen et al. [37], and on 353 by Olsen et al. [38].
These two latter papers reported data from 19 paediatric
departments (both) and five/six departments of internal
medicine, whereas Salardi et al. [40] reported data from
eleven centres; the other four papers did not provide detail.
Retinopathy was assessed and measured according to
current best practice guideline recommendations in all pa-
pers. In these seven studies from four different countrieswith participants sampled by different methods, retinopathy
prevalence varied somewhat (Table 1). Salardi et al. [40] re-
ported an overall prevalence of 40%, with 27% and 88% at
less than or greater than 20 years diabetes duration, re-
spectively, whereas James et al. [34] reported a prevalence
of 13.7% and 9.4%, and Olsen et al. [38] 57.6%; LeCaire
et al. [36] reported 47% with retinopathy at nine years dia-
betes duration (6% - 73% with retinopathy at mean ages
19.5 - 24.8 years). At similar diabetes duration proliferative
or treated diabetic retinopathy was reported in 10.2% of
participants by Arfken et al. [31], but affected 0.3% of those
at nine years diabetes duration by LeCaire et al. [36]; Broe
et al. [32] reported a prevalence of proliferative retinopathy
of 0.5% - 0.7%.
Data were provided relating to predictors of diabetic
retinopathy in the target population in only two of these
studies. Arfken et al. [31] reported that in White partici-
pants, a strong association was demonstrated between
the development of proliferative retinopathy and exist-
ing moderate/severe diabetic retinopathy (Odds Ratio
(OR) 16.55 (95% Confidence Interval (CI) 5.43 - 50.45)).
Glycaemic control was also shown to be significant (2%
change in HbA1c; OR 2.17 (95% CI 1.34 - 3.50)). This
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Table 1 Reported prevalence of diabetic retinopathy (Continued)
Hazard ratio 1.6 (* 0.8 - 3.0)
HbA1c (per 1%) by diabetes
duration (DR)
4 years Hazard ratio 1.1
(* 1.0 - 1.3)
7 years Hazard ratio 1.4
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14 years Hazard ratio 1.2
(* 1.0 - 1.6)
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20.4 (3.2) (Prepubertal diabetes onset), 24.2 (1.3) (Pubertal/post-pubertal
diabetes onset); n 304 (Prepubertal diabetes onset), n 49 (Pubertal/post-
pubertal diabetes onset ) (n 353 TS)




after the onset of puberty
(DR); p < 0.001
Salardi et al.
2012; Italy [40]
n 11 Very young pre-pubertal onset 22.0 (4.5); n 53 (n 105 TS) 40% Diabetes duration - <
20 yrs.: 27% > 20 yrs.: 88%
30% (M); 10%
(Mod - Sev)
(DR) Diabetic retinopathy (M) Mild (Min) Minimal (Mod) Moderate (n) Number (OR) Odds ratio (Sev) Severe (SD) Standard deviation.




















James et al. BMC Research Notes 2014, 7:593 Page 7 of 11
http://www.biomedcentral.com/1756-0500/7/593latter finding was consistent with Olsen et al. [38] who
reported long-term glycaemic control (p < 0.0001) and
diabetes duration before and after puberty onset (p <
0.05 and p < 0.001, respectively) as significantly associ-
ated with the development of retinopathy (Table 1).
Other findings were generated from samples inclusive
of but not specific to the target population.
Prevalence and prediction of nephropathy
Prevalence of diabetic nephropathy was reported in eight
papers [32-35,37-40]. Raile et al. [39] reported data from
262 centres and, as previously reported, Salardi et al.
[40] from eleven centres and both Olsen et al. [37] and
Olsen et al. [38], from 19 paediatric departments (both)
and five/six departments of internal medicine; the num-
ber of centres from which data were obtained was un-
clear in James et al. [34]. In all of these five papers renal
function indices employed were not in accordance with
current best-practice guideline recommendations. These
were however utilised by Broe et al. [32] who reported
18 (10.5%) and 17 (14.8%) participants with albuminuria,
and Garg et al. [33] who reported data from a single
eye/kidney clinic. In a study involving 150 participants,
24 (16%) were reported with albumin excretion indica-
tive of microalbuminuria and eleven (7.3%) with values
indicative of macroalbuminuria. Prevalence data were
also reported for 121 participants by Kullberg et al. [35].
For this study, neither number of study sites nor detail
of study assessment methods for nephropathy were sup-
plied. At recruitment for fundus photography sample
ages ranged mean (SD) 12.4 (2.1) - 41.7 (2.4) years, with
subgroups A3 aged 21.9 (2.2) years and A4 27.2 (2.3)
years. In these subgroups 14% and 13% were reported
with urinary albumin excretion greater than 20 mg/L.
Factors predicting development of nephropathy were not
reported by either Broe et al. [32] or Garg et al. [33].
Prevalence and prediction of hypertension
The prevalence of hypertension was reported in five pa-
pers [33-35,40,41]. Schwab et al. [41] and Salardi et al.
[40] reported data derived from 195 and eleven centres,
respectively, but did not detail young adult cohort num-
bers. As previously noted, Kullberg et al. [35] reported
prevalence data from 121 eligible participants but did
not detail numbers of sites.
Criteria for hypertension in adults with diabetes were
revised down to 130/80 mmHg earlier this century. All
three papers reported the prevalence of hypertension ei-
ther without stating diagnostic criteria or using what are
now out-dated criteria (140/90 mmHg). Kullberg et al.
[35] and Salardi et al. [40] reported hypertension by their
definitions as occurring in 0% - 9% of participants.
Schwab et al. [41] reported raised systolic and diastolic
blood pressures in 11% and 2.6% of applicableparticipants, respectively, with 4.8% receiving pharmaco-
therapy. Out-dated criteria were also used by Garg et al.
[33] who reported blood pressure values categorised by
participants’ albumin excretion rate grouping. They re-
ported 34% - 72.5% of systolic and 37.7% - 64.9% of dia-
stolic ambulatory blood pressure measurements (mean
of 24-hour collections) as above the 90% percentile of
normal for age, gender and ethnic group. For partici-
pants with macroalbuminuria, over 60% of day and
night-time systolic and diastolic measurements were
above the 90th percentile of normal values.
Indices employed by James et al. [34] were in accord-
ance with current best-practice guideline recommenda-
tions. Blood pressure measurements were documented
in 313 and 306 of participants, with 33.9% and 30.7%
having mean values within hypertensive ranges, respect-
ively. With anti-hypertensive medication prescribed for
10.2% of participants a total of 201 (48.4%) were classi-
fied as hypertensive; at least one documented hyperten-
sive measurement was reported in 35 (48.6%) cohort
members prescribed anti-hypertensive medication,
across the study period. Participants were more likely to
have hypertension if they had no (rather than any) health
service contact (OR 0.21, 95% CI 0.1 - 0.51, p = 0.001) or
a longer diabetes duration (each year, OR 1.05, 95% CI
1.01 - 1.09, p = 0.006). This was in addition to use of
continuous subcutaneous insulin infusion therapy (OR
1.8, 95% CI 1.2 - 2.7, p = 0.004) although this latter find-
ing may have been affected by missing data.Discussion
This systematic literature review indicated that vascular
complications are common amongst young adults with
type 1 diabetes although the results reported varied
somewhat. Some form of retinopathy occurred in up to
almost half of participants; more severe forms affected
up to one in ten. One in six was reported with microal-
buminuria; one in 14 had macroalbuminuria. Hyperten-
sion occurred in almost one in two participants. In out-
dated high thresholds this decreased to approximately
one in ten participants. The frequency of these compli-
cations is concerning since they are largely preventable,
are occurring alongside an increasing incidence of type 1
diabetes worldwide, and incur high costs in financial and
health-related quality of life terms. Ng and Morlet [45]
flagged the high prevalence and cost of diabetic retinop-
athy amongst Australians, but failed to differentiate the
particular problems of younger onset and hence greater
lifetime burden for those with type 1 diabetes. The Dia-
bCo$t Australia study [46] estimated the minimum an-
nual cost of type 1 diabetes in Australia at between $430
to $570 million in 2008, with expenditure increasing
with the presence of complications. Real costs were
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ity and premature mortality were not considered.
Identified prevalence rates of retinopathy in this young
adult population were elevated compared to recent data
for adolescents with type 1 diabetes. Downie et al. [47]
reported a prevalence of 12% between 2005–2009, com-
pared to up to 40% and 57.6% in the literature reviewed
here [38,40]. The review rate was not dissimilar to rates
provided for older cohorts of people with type 1 diabetes
(within a decade outside the review age criteria). Karadeniz
and Yilmaz [48], Esteves et al. [49] and Roy [50] reported
retinopathy prevalence of 33.2%, 44.4% and 63.9%, respect-
ively; discrepancies perhaps reflected the trend of increasing
prevalence of complications with increasing diabetes dur-
ation and age.
In studies where data were obtained using current best
practice recommendations, prediction of development of
nephropathy was not reported for the young adult age
group. Studies of older cohorts of people with type 1
diabetes found diabetic nephropathy associated with
indices of diabetes duration and control (increasing
HbA1c), and with prevalence and severity of other forms
of vascular disease and population-wide markers of vas-
cular risk such as triglyceride levels and weight [51-55].
The identified prevalence rates of hypertension in this
young adult population were also elevated compared to
a study involving a slightly older cohort (mean (SD) age
33.8 (11.8) years at baseline), which reported an increase
in elevated systolic and diastolic blood pressures over
time. In 2003–2004, 17.9% and 6%, respectively, were
affected, whereas by 2006–2007 this had increased to 28.8%
and 8.2%. The proportion of participants prescribed anti-
hypertensive medication also increased significantly during
this period, from 20.7% to 34.2% [56]. However, in another
similarly older cohort (mean (SD) age 37 (9) years) only
48% of those diagnosed and treated for hypertension
achieved target values [57], indicating little room for com-
placency. This is consistent with review findings.
The paucity of blood pressure data for young adults
and the indication of poor achievement of treatment
goals are particular concerns. Hypertension predisposes
to stroke, myocardial infarction, cardiac failure and limb
amputation as well as other vascular disease manifesta-
tions such as retinopathy and nephropathy. A trend seen
in slightly older young adults with type 1 diabetes was of
any one end-organ manifestation of vascular disease in-
dicating an increased likelihood of concurrent vascular
disease in other areas. For example, in cohorts with
mild/severe renal failure, 71.4% and 83.3%, respectively,
also had hypertension [58]. Early detection and prompt
treatment are therefore essential, with general popula-
tion studies clearly demonstrating early diagnosis and
adherence to treatment prevents or delays development
and progression of end-organ damage [59].Adherence to sometimes complex, always life-long
medication schedules is challenging. ‘Typical’ versus
‘ideal’ medication adherence in patients with hyperten-
sion has demonstrated nearly double the relative risk
of myocardial infarction, angina and stroke [60]. How-
ever, Hill et al. [61] cited achievement of up to 80%
adherence rates in routine care and this is especially
important for this patient group as cardiovascular dis-
ease occurs more than ten times more frequently in
those with type 1 diabetes than in age-matched non-
diabetes populations [62]. Lack of data on the preva-
lence of hypertension may hamper prioritisation and
appropriate targeting of therapy; important opportun-
ities for treatment may be missed.
Effective prevention interventions rely on identifying
modifiable predictors of vascular complications. Data re-
lating specifically to the target population were scarce
and this quantitative epidemiological systematic review
found glycaemic control as predictive of vascular disease
in young adults with type 1 diabetes. Diabetes duration
was also flagged, of concern because it is not modifiable
and almost half of those who develop the disease do so
before age 15 years, many in infancy and childhood [63].
After only nine years with type 1 diabetes almost half of
young adults had retinal damage [36] - and probably
other vascular disease as well.
On the other hand glycaemic control is modifiable and
influential. The deterioration that accrues with disease
duration may be ameliorated by better glycaemic control
[9,64], with better control being achieved by those who
maintain contact and relationships with their diabetes
healthcare teams [65]. This flags the crucial importance
of ensuring that services are able to support young
adults with type 1 diabetes, particularly during the vul-
nerable period when they leave the paediatric services
that supported them as children, establish relationships
with adult services and independent self-management
practices. It reinforces the importance of regular screen-
ing using best practice methods as this offers the best
chance for early detection and initiation of appropriate
treatment, and consequently to minimise visual loss and
blindness, renal failure and dialysis, heart failure and
strokes occurring in young adults.
Good quality data are required from adequately pow-
ered studies to inform service development, to help
nurses and other healthcare professionals risk-stratify
and provide appropriate support to young adults with
type 1 diabetes, to minimise and defer onset of vascular
complications. In most developed countries the data re-
quired for high-powered studies are collected routinely
by diabetes services. That these data have not been
accessed and used to develop algorithms to stratify risk
for these young adults is indicative of the lack of priority
accorded this problem.
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for grey literature such as conference abstracts was not
undertaken; neither were experts in this field contacted
for unpublished data, nor authors for data from age-
specific subsets where these data did not appear in pub-
lications. Identification of a specific age range to desig-
nate ‘young adults’ was challenging; we opted to focus
on those who would have transitioned out of paediatric
into adult care, but use of wider age ranges may have
yielded additional data.
Caution also needs to be exercised when considering
how review findings can be generalised to the target
population of young adults with type 1 diabetes as few
studies focused solely on representative samples of this
specific age group or involved rural populations. Other
omissions were the paucity of studies undertaken in devel-
oping countries, and limited data indicating participants’
ethnicity. Finally, although studies reporting data collected
pre 1993 were excluded in light of the definitive Diabetes
Control and Complications Trial [9], it may have taken a
number of years for these research findings to change
practice such that glycaemic control became central in
every-day management. Earlier literature reviewed may
therefore be poorly representative of current practice and
not reflect prevalence of vascular complications in today’s
young adults. New primary research is required.
Conclusion
This is the first systematic review of the prevalence and
predictors of retinopathy, nephropathy and hypertension
in young adults with type 1 diabetes. While data were
limited, underlying vascular disease manifesting as retinop-
athy and hypertension was common amongst this group,
with development predicted by glycaemic control - and
probably diabetes duration. With only one of these two fac-
tors amenable to clinical management, findings have impli-
cations for clinicians, policy-makers, patients and families:
to raise the priority of improving glycaemic control as a
means to defer and avoid development of complications
which otherwise appear near-inevitable.
Clinical messages of this review are the importance of
prevention of loss to follow up and provision of appro-
priate support, particularly around the vulnerable transi-
tion period from paediatric to adult-based care. This
would ensure support for optimal glycaemic control and
enable regular complication screening to be imple-
mented - essential for early detection and treatment in
this age group. Quality data are required to be available
to clinicians and patients to stratify risk and guide treat-
ment planning, and to inform service development. The
message for policy-makers is that the prevalence rates
identified make good preventive care essential. The chal-
lenge is to make this a realistic option and available to
all young adults with type 1 diabetes.Additional files
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